Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents

References

• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Suciu S, Baila L, . Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29:1987–1996.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Gattermann N, Seymour JF, . Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010;149: 244–249.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thepot S, Quesnel B, . Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403–411.
   PubMed Web of Science ®Google Scholar
• List AF, Fenaux P, Mufti GJ, . Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. J Clin Oncol 2008;26(15 Suppl.) Abstract 7006.
   Google Scholar
• Moon JH, Kim SN, Kang BW, . Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. Ann Hematol 2010;89:681–689.
   PubMed Web of Science ®Google Scholar
• Wijermans PW, Lubbert M, Verhoef G, . An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005;84(Suppl. 1):9–17.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Shan J, . Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109: 265–273.
   PubMed Web of Science ®Google Scholar
• Breccia M, Loglisci G, Cannella L, . Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to evaluate overall survival and rate of response. Leuk Lymphoma 2012;53:982–983.
   PubMed Web of Science ®Google Scholar
• van der Helm LH, Alhan C, Wijermans PW, . Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011;155:599–606.
   PubMed Web of Science ®Google Scholar
• Koreth J, Pidala J, Perez WS, . A decision analysis of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for older patients with de-novo myelodysplastic syndrome (MDS): early transplantation offers survival benefit in higher-risk MDS. Blood 2011;118(Suppl. 1): Abstract 115.
   Google Scholar
• Prebet T, Gore SD, Esterni B, . Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;29:3322–3327.
   PubMed Web of Science ®Google Scholar
• Sanna A, Cannella L, Gozzini A, . Comorbidities indexes in patients treated with 5-azacitidine are a an useful and easily applicable tool to refine prognostic evaluation. Blood 2010;116 (Suppl. 1): Abstract 606.
   Google Scholar
• Fandy TE, Herman JG, Kerns P, . Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114:2764–2773.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, . Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52–57.
   PubMed Web of Science ®Google Scholar
• Shen L, Kantarjian H, Guo Y, . DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605–613.
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, . Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107:7473–7478.
   PubMed Web of Science ®Google Scholar
• Braun T, Itzykson R, Renneville A, . Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase II trial. Blood 2011;118:3824–3831.
   PubMed Web of Science ®Google Scholar
• Follo MY, Finelli C, Mongiorgi S, . Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA 2009;106:16811–16816.
   PubMed Web of Science ®Google Scholar
• Tiu RV, Visconte V, Traina F, . Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep 2011;6:126–135.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553–567.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, . Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25:1147–1152.
   PubMed Web of Science ®Google Scholar
• Traina F, Jankowska AM, Visconte V, . Impact of molecular mutations on treatment response to hypomethylating agents in MDS. Blood 2011;118(Suppl. 1): Abstract 461.
   Google Scholar
• Walker AR, Metzeler KH, Geyer S, . Impact of DNMT3A mutations on clinical response to the hypomethylating agent decitabine in older patients (pts) with acute myeloid leukemia (AML). Blood 2011;18(Suppl. 1): Abstract 944.
   Google Scholar
• Grossmann V, Kohlmann A, Eder C, . Analyses of 81 chronic myelomonocytic leukemia (CMML) for EZH2, TET2, ASXL1, CBL, KRAS, NRAS, RUNX1, IDH1, IDH2, and NPM1 revealed mutations in 86.4% of all patients with TET2 and EZH2 being of high prognostic relevance. Blood 2010;116(Suppl. 1): Abstract 296.
   Google Scholar